This week, three Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
YM BioSciences (AMEX:YMI) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. YM BioSciences is a drug development company, engages in advancing three clinical-stage hematology and cancer-related products. In Portfolio Grader’s specific subcategories of Earnings Revisions and Sales Growth, YMI also gets A’s. For more information, get Portfolio Grader’s complete analysis of YMI stock.
Keryx Biopharmaceuticals (NASDAQ:KERX) shows solid improvement this week. The company’s rating rises from a C to a B. Keryx Biopharmaceuticals focuses on developing and commercializing pharmaceuticals for the treatment of cancer and renal disease. The stock price has risen 26.3% over the past month, better than the 0.1% the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of KERX stock.
Synergy Pharmaceuticals (NASDAQ:SGYP) earns a B this week, jumping up from last week’s grade of C. Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. Wall Street has pushed the stock higher by 56% over the past month. For more information, get Portfolio Grader’s complete analysis of SGYP stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.